Venlafaxine: Difference between revisions
| Line 16: | Line 16: | ||
==Overview== | ==Overview== | ||
'''Venlafaxine''' ([[brand name]]: '''Effexor''' or '''Efexor''') is an [[antidepressant]] of the [[serotonin-norepinephrine reuptake inhibitor]] (SNRI) class.<ref name="pmid3790168">{{cite journal |author=Muth, EA; Haskins, JT; Moyer, JA; Husbands, GE; Nielsen, ST; Sigg, EB |title=Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative |journal=Biochemical Pharmacology |volume=35 |issue=24 |pages=4493–7 |date=December 1986 |pmid=3790168 |doi=10.1016/0006-2952(86)90769-0}}</ref><ref name="pmid1976813">{{cite journal |author=Yardley, JP; Husbands, GE; Stack, G; Butch, J; Bicksler, J; Moyer, JA; Muth, EA; Andree, T; Fletcher, H 3rd; James, MN; ''et al.'' |title=2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity |journal=Journal of Medicinal Chemistry |volume=33 |issue=10 |pages=2899–905 |date=October 1990 |pmid=1976813 |doi=10.1021/jm00172a035 |url=}}</ref><ref name="pmid11750180">{{cite journal |author=Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw, JL; Thompson, L; Nelson, DL; Hemrick-Luecke, SK; Wong, DT |title=Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors |journal=Neuropsychopharmacology |volume=25 |issue=6 |pages=871–80 |date=December 2001 |pmid=11750180 |doi=10.1016/S0893-133X(01)00298-6 |url=http://www.nature.com/npp/journal/v25/n6/pdf/1395741a.pdf |format=PDF}}</ref> First introduced by [[Wyeth]] in 1993, now marketed by [[Pfizer]], it is [[licensed]] for the treatment of [[major depressive disorder]] (MDD), as a treatment for [[generalized anxiety disorder]], and [[comorbid]] [[Indication (medicine)|indications]] in certain [[anxiety disorders]] with depression. In 2007, venlafaxine was the sixth most commonly prescribed antidepressant on the U.S. retail market, with 17.2 million prescriptions.<ref>The number of prescriptions was calculated as the total of prescriptions for the corresponding generic and brand-name drugs using data from the charts for generic and brand-name drugs. {{cite web |title=Top 200 generic drugs by units in 2007. |work=Drug Topics, Feb 18, 2008 |url=http://drugtopics.modernmedicine.com/drugtopics/Top200Drugs/ArticleStandard/article/detail/491194 |archiveurl=https://web.archive.org/web/20090718184023/http://drugtopics.modernmedicine.com/drugtopics/Top200Drugs/ArticleStandard/article/detail/491194 |archivedate=18 July 2009 |accessdate=23 October 2008}}</ref> | |||
==Category== | ==Category== | ||
Revision as of 04:13, 10 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Venlafaxine, click here
Synonyms / Brand Names: EFFEXOR XR®
 |
Overview
Venlafaxine (brand name: Effexor or Efexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class.[1][2][3] First introduced by Wyeth in 1993, now marketed by Pfizer, it is licensed for the treatment of major depressive disorder (MDD), as a treatment for generalized anxiety disorder, and comorbid indications in certain anxiety disorders with depression. In 2007, venlafaxine was the sixth most commonly prescribed antidepressant on the U.S. retail market, with 17.2 million prescriptions.[4]
Category
FDA Package Insert
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
References
- ↑ Muth, EA; Haskins, JT; Moyer, JA; Husbands, GE; Nielsen, ST; Sigg, EB (December 1986). "Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative". Biochemical Pharmacology. 35 (24): 4493–7. doi:10.1016/0006-2952(86)90769-0. PMID 3790168.
- ↑ Yardley, JP; Husbands, GE; Stack, G; Butch, J; Bicksler, J; Moyer, JA; Muth, EA; Andree, T; Fletcher, H 3rd; James, MN; et al. (October 1990). "2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity". Journal of Medicinal Chemistry. 33 (10): 2899–905. doi:10.1021/jm00172a035. PMID 1976813.
- ↑ Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw, JL; Thompson, L; Nelson, DL; Hemrick-Luecke, SK; Wong, DT (December 2001). "Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors" (PDF). Neuropsychopharmacology. 25 (6): 871–80. doi:10.1016/S0893-133X(01)00298-6. PMID 11750180.
- ↑ The number of prescriptions was calculated as the total of prescriptions for the corresponding generic and brand-name drugs using data from the charts for generic and brand-name drugs. "Top 200 generic drugs by units in 2007". Drug Topics, Feb 18, 2008. Archived from the original on 18 July 2009. Retrieved 23 October 2008.